Zunveyl for Alzheimer's disease symptoms and caregiver support
Part of Brain & nervous system, Mental health clinical trials.
This study tests a medication called Zunveyl to see if it helps reduce behavioral and neuropsychiatric symptoms in people with mild-to-moderate Alzheimer's disease, and whether it reduces stress on family caregivers. You would need a confirmed Alzheimer's diagnosis supported by a blood test, and a dedicated caregiver who can attend visits and report on your symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 50 or older with a confirmed Alzheimer's disease diagnosis verified by a specific blood test (pTau217/β-Amyloid 1-42 ratio)
- Mild-to-moderate cognitive impairment shown by a memory screening test (SLUMS exam)
- A full-time caregiver or study partner available at least 20 hours per week who can attend all visits and track your symptoms
- Stable doses of any current medications for at least 4 weeks before starting the study
- No recent psychiatric hospitalization, active psychosis, or significant gastrointestinal problems that affect medication absorption
- Willingness to attend outpatient visits and complete memory and symptom assessments throughout the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called LY3439539 in people with early-stage Alzheimer's disease. The drug is designed to target protein changes in the brain that may slow memory loss and cognitive decline.
This trial tests whether galcanezumab, an antibody injection, can help people with mild-to-moderate Alzheimer's disease. It is for patients who have a confirmed Alzheimer's diagnosis and a caregiver who can support them.
This trial tests whether a daily pill called ozanimod can help people with moderate Alzheimer's disease. The study monitors changes in thinking and memory over time and requires a study partner who can join visits.
This study tests an experimental drug (KarXT) to see if it safely reduces agitation in people with Alzheimer's disease. It may help if you or your loved one experiences restlessness, aggression, or irritability related to Alzheimer's.
This Phase 2 trial tests an oral medicine (EX039) to see if it can help people with mild Alzheimer’s disease. It focuses on slowing or improving thinking and memory problems over time.
This study tests a new drug called NSC001 for people with mild to moderate Alzheimer's. It checks if the drug is safe and if it might help slow memory decline. You'll need a caregiver who can join you at visits and help track your progress.
Hear when a new Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.